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Background: The function of VASP in regulating 
actin polymerization during airway smooth muscle 
contraction is unknown. 
Results: VASP activity requires phosphorylation 
at Ser157, recruitment to the membrane, and 
interaction with activated vinculin.  
Conclusion: VASP regulates actin polymerization 
and contraction in smooth muscle by a unique   
mechanism.  
Significance. The mechanism of VASP function is 
important for understanding actin dynamics in 
cells.  
 
ABSTRACT  
Vasodilator stimulated phosphoprotein 
(VASP) can catalyze actin polymerization by 
elongating actin filaments. The elongation 
mechanism involves VASP oligomerization and 
its binding to profilin, a G-actin chaperone. 
Actin polymerization is required for tension 
generation during the contraction of airway 
smooth muscle (ASM); however the role of 
VASP in regulating actin dynamics in ASM is 
not known. We stimulated ASM cells and 
tissues with the contractile agonist acetylcholine 
(ACh) or the adenylyl cyclase activator, 
forskolin (FSK), a dilatory agent. ACh and 
FSK stimulated VASP Ser157 phosphorylation 
by different kinases.  Inhibition of VASP 
Ser157 phosphorylation by expression of the 
mutant VASP S157A in ASM tissues 
suppressed VASP phosphorylation and 
membrane localization in response to ACh, and 
also inhibited contraction and actin 
polymerization.  ACh but not FSK triggered 
the formation of VASP-VASP complexes as 
well as VASP-vinculin and VASP-profilin 
complexes at membrane sites. VASP-VASP 
complex formation and the interaction of VASP 
with vinculin and profilin were inhibited by 
expression of the inactive vinculin mutant, 
vinculin Y1065F, but VASP phosphorylation 
and membrane localization were unaffected. 
We conclude that VASP phosphorylation at 
Ser157 mediates its localization at the 
membrane, but that VASP Ser157 
phosphorylation and membrane localization is 
not sufficient to activate its actin catalytic 
activity. The interaction of VASP with 
activated vinculin at membrane adhesion sites 
is a necessary prerequisite for VASP-mediated 
molecular processes necessary for actin 
polymerization. Our results show that VASP is 
a critical regulator of actin dynamics and 
tension generation during the contractile 
activation of ASM. 
 
Dynamic remodelling of the actin 
cytoskeleton is recognized as an important step in 
the agonist-induced activation of contraction and 
tension development in airway smooth muscle 
(ASM) and in other smooth muscle tissues (1). 
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The regulation of actin filament remodelling is a 
complex process involving the coordinated 
activity of multiple proteins; but the molecular 
mechanisms for actin remodelling and the 
processes by which actin regulatory proteins are 
activated in response to contractile and dilatory 
agents in smooth muscle tissues are poorly 
understood. In ASM, neuronal Wiskott-Aldrich 
syndrome protein (N-WASp) plays a critical role 
in the initiation of actin polymerization during 
contractile stimulation by activating the Arp2/3 
complex (2). The Arp2/3 complex is believed to 
nucleate the formation of new actin filaments that 
branch off the sides of existing filaments (3).  
However, the importance of other catalysts for 
actin polymerization in regulating the contraction 
of ASM has not been determined.  
Members of the Ena/VASP family regulate 
cell motility and shape in a wide variety of cell 
types (4,5). While a number of molecular 
functions that affect actin dynamics have been 
attributed to Ena/VASP proteins, there is extensive 
evidence for their role as actin filament elongation 
factors, i.e. they bind to the barbed (fast growing) 
ends of existing actin filaments and promote 
filament lengthening (4,6,7).  The mechanism for 
the elongation of actin filaments by VASP is 
proposed to require the assembly of VASP into  
tetrameric oligomers and the membrane 
recruitment and anchoring of VASP to the 
scaffolding proteins vinculin and zyxin at sites of 
actin filament assembly. Filament elongation  can 
then occur via the recruitment of profilin-G actin 
complexes to bind to VASP tetramers, followed by 
the transfer and assembly of G actin monomers 
into the barbed ends of the actin filaments that are 
also bound to VASP (8-10). We evaluated ASM 
for evidence of a VASP-mediated process of actin 
elongation during contractile and dilatory 
stimulation.  
Ena/VASP proteins consist of 3 domains, N 
and C-terminal Ena/VASP homology 1 and 2 
(EVH) domains and a central proline-rich region 
(PRR)(4,7).  The EVH1 domain contains binding 
sites for several focal adhesion scaffolding 
proteins including vinculin; the PRR region 
contains binding sites for profilin-actin, a primary 
source of actin monomers for actin filament 
polymerization; and the EVH2 domain contains 
binding sites for filamentous (F) and globular (G) 
actin.  The C-terminal coiled-coil region within the 
EVH2 domain of VASP mediates the assembly of 
VASP monomers into stable tetramers, believed to 
be an essential step for VASP to function as an 
elongation factor (4,8,11-15). Ena/VASP proteins 
are also known substrates for both serine/threonine 
and tyrosine kinases (16-18). The phosphorylation 
of VASP Ser157 has been implicated in the 
cellular localization of VASP (17,19). VASP plays 
a role in the regulation of actin polymerization and 
contraction in aortic smooth muscle (20). VASP is 
expressed in ASM tissues and undergoes 
phosphorylation at Ser157 during β adrenergic 
stimulation (21,22); but the function of VASP 
during the contraction and relaxation of ASM is 
unknown. 
Signaling events that regulate actin 
polymerization during contractile stimulation of 
ASM are mediated by adhesome complexes at 
integrin-ECM adhesion junctions (23). Vinculin, a 
VASP ligand, plays an important structural role in 
these junctions by binding to the integrin-binding 
proteins talin and α-actinin as well as to actin 
filaments (24). Vinculin can assume a closed 
conformation in which it does not bind to actin or 
talin, and an open conformation in which its actin 
and talin binding sites are exposed (25,26). The 
contractile stimulation of ASM tissues with ACh 
induces the recruitment of vinculin to membrane 
adhesion complexes and its activation to an open 
ligand-binding conformation (27,28). Vinculin 
phosphorylation on Tyr1065 is necessary for 
vinculin to sustain an activated conformation in 
which it can bind to talin and actin filaments (27). 
VASP has been shown to bind to the proline-rich 
hinge region of vinculin at cell junctions (29-31); 
thus we hypothesized that vinculin might play a 
role in the regulation of VASP-mediated actin 
dynamics in ASM. To test this hypothesis, we 
evaluated the molecular mechanisms by which 
contractile and dilatory stimuli regulate the 
activity of VASP and its interaction with vinculin 
in ASM.  
Our results suggest that VASP functions as an 
actin elongation factor at the ASM plasma 
membrane, and that the interaction of VASP with 
activated vinculin is prerequisite to this function. 
We conclude that VASP is an important catalyst 
for actin polymerization during the contraction of 
ASM tissues.  
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EXPERIMENTAL PROCEDURES 
Preparation of smooth muscle tissues and 
measurement of force.  Mongrel dogs were 
euthanized in accordance with the guidelines of 
the Institutional Animal Care and Use Committee 
(IACUC), Indiana University School of Medicine. 
The trachea was immediately removed and 
immersed in physiological saline solution (PSS) at 
22 o C. The solution was aerated with 95% O2 -5% 
CO2 to maintain a pH of 7.4. Rectangular strips of 
tracheal muscle 1 mm in diameter and 10 mm in 
length were dissected after removal of the 
epithelium and connective tissue layer. Each 
muscle strip was placed in PSS at 37oC in a 25 ml 
organ bath and attached to a Grass force 
transducer for the measurement of force. At the 
beginning of each experiment, muscle length was 
progressively increased until the force of active 
contraction in response to a contractile stimulus 
reached a maximum (optimal length). 
Reagents and antibodies.  Antibodies used in 
these experiments were: mouse monoclonal 
human VASP (BD Biosciences Pharmingen), 
rabbit polyclonal human VASP (Cell Signaling), 
mouse  monoclonal human VASP phospho-Ser157 
(Abcam), mouse monoclonal human VASP 
phospho-Ser239 (Millipore); rabbit polyclonal 
human VASP phospho-Ser239 (Cell Signaling); 
rabbit polyclonal GFP (MBL); rabbit His-tag (Cell 
Signaling), rabbit polyclonal bovine myosin light 
chain, custom made by BABCO (Richmond, CA); 
polyclonal vinculin (against canine cardiac 
vinculin); mouse monoclonal human profilin1 
(Abcam); rabbit polyclonal human profilin 
(Cytoskeleton); mouse monoclonal human actin 
(Sigma); Alexa Fluor 488 and 546 (Invitrogen); 
IRDye 800CW goat anti-mouse IgG and IRDye 
680LT goat anti-rabbit IgG (Li-Cor). 
Reagents included Duolink in situ proximity 
ligation kit (PLA) and anti-mouse plus and anti-
rabbit minus probes (Olink Bioscience, Uppsala, 
Sweden), lysis and F-Actin stabilization buffers 
(Cytoskeleton), protein kinase C inhibitor 
Bisindolylmaleimide I (BIM) (Sigma). Plasmid 
vectors used included pcDNA3 EGFP  full length 
human VASP and VASP S157A (alanine 
substituted at Ser157, 6xHis tagged) (17,18), 
pEGFP-vinculin full-length chicken vinculin 
(residues 1-1066) (32); and non-phosphorylatable 
vinculin Y1065F (27).  
Introduction of plasmids into tracheal 
smooth muscle tissues. Plasmids encoding full 
length EGFP VASP and EGFP VASP S157A were 
introduced into the smooth muscle strips by the 
method of reversible permeabilization as previously 
described (2,33-36).  Muscle tissues were attached 
to a metal hooks and incubated successively in each 
of the following solutions: Solution 1, which 
contained 10 mM EGTA, 5 mM Na2ATP, 120 mM 
KCl, 2 mM MgCl2 and 20 mM N-tris 
(hydoxymethyl) methyl-2-aminoethanesulfonic acid 
(TES) (at 4º C, pH 7.1,100% O2  for 120 min);  
Solution 2, which contained  0.1 mM EGTA, 5 mM 
Na2ATP, 120 mM KCl, 2 mM MgCl2, and 20 mM 
TES and 10 µg/ml plasmids (at 4º C, pH 7.1, 
overnight); Solution 3, which contained  0.1 mM 
EGTA, 5 mM Na2ATP, 120 mM KCl, 10 mM 
MgCl2 and 20 mM TES (at 4ºC, pH 7.1, 100% O2 
for 30 min); and Solution 4, which contained 110 
mM NaCl, 3.4 mM KCl, 0.8 mM MgSO4, 25.8 mM 
NaHCO3, 1.2 mM KH2PO4 (at 22º C, pH 7.4 for 60 
min and aerated with 95% O2 and 5% CO2). After 
30 min in Solution 4, CaCl2 was added gradually to 
reach a final concentration of 2.4 mM. The 
plasmid-treated tissue strips were then incubated at 
37º C for 2 days in DMEM containing 5 mM 
Na2ATP, 100 U/ml penicillin, 100 µg/ ml 
streptomycin, and 10 μg/ml plasmids to allow for 
expression of the recombinant proteins. Sham-
treated tissues were subjected to identical 
procedures except that no plasmids were included 
in Solution 2. Tissues were then quickly frozen 
using liquid N2 cooled tongs for biochemical 
analysis or they were dissociated for cellular 
imaging studies. 
Immunoblot and Immunoprecipitation.  
Frozen muscle tissues were pulverized, and the 
proteins were extracted for electrophoresis or 
immunoprecipitation as previously described 
(2,28). For immunoprecipitation, the extracts were 
precleared at 4°C with protein A/G UltraLink 
Resin and incubated with antibodies against the 
target protein. Western blotting of 
immunoprecipitates or muscle extracts was 
performed to quantitate proteins. The proteins 
were visualized by ECL and digitally quantified 
using a Bio-Rad ChemiDoc XRS detection system, 
 VASP phosphorylation at Ser157 was 
quantitated by probing membranes simultaneously 
with mouse anti-phospho-Ser157 VASP Ab 
(Abcam) and polyclonal rabbit anti-VASP Ab 
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(Cell Signaling), and then using fluorescent probes 
to detect both antibodies simultaneously using a 
Li-Cor Odyssey infrared imaging system. 
Myosin Light Chain Phosphorylation. 
Muscle strips were rapidly frozen and then 
immersed in acetone containing 10% (w/v) 
trichloroacetic acid and 10 mM DTT that was 
precooled with dry ice. Strips were thawed in 
acetone-trichloroacetic acid-DTT at room 
temperature and then washed 4 times with 
acetone-DTT. Proteins were extracted for 2-3 
hours in 8M urea, 20 mM Tris base, 22 mM 
glycine, and 10 mM DTT. Myosin light chains 
(MLCs) were separated by glycerol-urea 
polyacrylamide gel electrophoresis, transferred to 
nitrocellulose and incubated with polyclonal rabbit 
MLC 20 antibody (2,37,38). Unphosphorylated 
and phosphorylated bands of MLCs were 
visualized by ECL and quantified by densitometry. 
MLC phosphorylation was calculated as the ratio 
of phosphorylated MLCs to total MLCs for each 
sample.  
Cell dissociation and analysis of protein 
localization. Smooth muscle cells were 
enzymatically dissociated from tracheal muscle 
strips, plated onto glass slides and allowed to 
adhere for 60 minutes as previously described 
(2,35). After cells were stimulated with ACh, FSK 
or left unstimulated, cells were then fixed and 
visualized for EGFP fluorescence or stained for 
immunofluorescence analysis. The effects of 
stimulation with ACh or FSK on the localization 
of proteins were evaluated in freshly dissociated 
smooth muscle cells using a Zeiss LSM 510 
confocal microscope. Images of smooth muscle 
cells were analyzed for regional differences in 
fluorescence intensity by quantifying the pixel 
intensity with a series of cross-sectional line scans 
along the entire length of each cell, excluding the 
nucleus (2,35). The ratio of pixel intensity 
between the cell periphery and the cell interior was 
computed for each line scan by calculating the 
ratio of the average maximum pixel intensity at the 
cell periphery to the average minimum pixel 
intensity in the cell interior. The ratios of pixel 
intensities between the cell periphery and the cell 
interior for all line scans performed on a given cell 
were averaged to obtain a single value for each 
cell.  
     In Situ Proximity Ligation Assay (PLA).  In 
situ proximity ligation assays were performed to 
detect interactions between VASP and vinculin, 
VASP and profilin, VASP-VASP complexes, and 
phospho-Ser157 VASP in dissociated cells. PLA 
provides a method for the precise detection of 
protein-protein complexes or interactions and 
protein modifications.  Two primary antibodies 
against the target proteins or protein epitopes are 
raised in different species, and a pair of 
oligonucleotide-labeled secondary antibodies (+ 
and − PLA probes) are targeted to each pair of 
primary antibodies. The probes form circular DNA 
strands only when they are bound in very close 
proximity (<40 nm). These DNA circles serve as 
templates for localized rolling circle amplification, 
generating a fluorescent signal (spot) that enables 
individual interacting pairs of the target protein 
molecules to be visualized. The PLA signal thus 
allows for the detection of a complex between two 
target proteins at a very high resolution (39,40). 
 Smooth muscle cells were fixed, 
permeabilized and incubated with a pair of 
primary antibodies of different species against two 
target proteins followed by a pair of 
oligonucleotide-labeled secondary antibodies 
(Duolink + and − PLA probes).  Mouse anti-VASP 
and rabbit anti-vinculin antibodies were used to 
probe VASP-vinculin interactions, rabbit anti-
VASP and mouse anti-profilin antibodies were 
used to probe VASP-profilin interactions, rabbit 
anti-VASP and mouse anti-VASP phospho-Ser157 
antibodies were used to detect VASP phospho 
Ser157, and mouse and rabbit phospho-Ser239 
VASP antibodies were used to detect VASP-
VASP interactions.  PLA probe hybridization, 
ligation, amplification and detection media were 
administered according to the manufacturer's 
instructions (Olink Bioscience, Uppsala, Sweden). 
Cells from unstimulated and ACh or FSK-
stimulated groups were analyzed for interactions 
by counting PLA fluorescent spots using a Zeiss 
LSM510 confocal microscope. Duolink 
ImageTool software was used to quantitate PLA 
signals.   
Analysis of F-actin/G-actin Ratio. The 
concentration of F-actin and G-actin in smooth 
muscle tissues was measured using an assay kit 
from Cytoskeleton Inc. Each of the smooth muscle 
strips was homogenized in F-actin stabilization 
buffer. The supernatants of protein extracts (G-
actin fraction) were collected after high speed 
centrifugation at 150,000 g for 60 min at 37° C. 
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The pellets were resuspended in ice-cold distilled 
H2O plus 10 μM cytochalasin D and then 
incubated on ice for 1 hour to dissociate F-actin. 
The supernatant of the resuspended pellets was 
collected after centrifugation at 4º C. Equal 
volumes of the first supernatant (G-actin) or 
second supernatant (F-actin) were subjected to 
analysis by immunoblot using anti-actin antibody. 
The amount of F-actin and G-actin was 
determined by densitometry and the ratio of F-
actin to G-actin was used for the analysis.  
Statistics. Data are expressed as means ± SE. 
Differences between treatment groups were 
determined using paired or unpaired two-tailed 
Student's t-test or ANOVA.  Differences were 
considered statistically significant when p< 0.05. 
 
 
RESULTS 
Stimulation with ACh, forskolin (FSK) or 
epinephrine induces VASP phosphorylation at 
the cell membrane in ASM. VASP 
phosphorylation at Ser157 was measured in ASM 
tissues stimulated with 10-4 M or 10-5 M ACh for 
time periods up to 30 min (Fig.1A). The shift in 
apparent molecular mass of VASP from 46 to 50 
kD by SDS-PAGE was used to analyze 
stoichiometric changes in the phosphorylation of 
VASP at Ser157. We confirmed that the 50 kD 
band was serine 157 phosphorylated VASP by 
simultaneously probing each membrane using a 
site-specific VASP Phospho-Ser157 antibody (Fig. 
1A,B) (41). Tissues were also stimulated with 
FSK for up to 20 min to evaluate VASP 
phosphorylation at Ser157 (Fig. 1A,B). VASP 
Ser157 phosphorylation increased significantly 
with both ACh and FSK stimulation, approaching 
a maximum by 10 min (Fig.1C). FSK induced 
significantly higher levels of VASP Ser157 
phosphorylation than ACh. Stimulation of muscles 
with the adrenergic hormone epinephrine affected 
VASP Ser157 phosphorylation similarly to FSK, 
but with a somewhat more rapid time course (Fig. 
1A,B). 
The PKC inhibitor bisindolylmaleimide I 
(BIM) (42) was used to determine whether PKC is 
involved in the regulation of VASP Ser157 
phosphorylation in response to ACh or FSK. 
Tracheal smooth muscle tissues were treated with 
10 μM BIM and then stimulated them with ACh or 
FSK (Fig.1D,E). BIM treatment significantly 
suppressed ACh induced VASP Ser157 
phosphorylation but it did not affect VASP 
phosphorylation stimulated by FSK, indicating 
that PKC mediates VASP Ser157 phosphorylation 
in response to stimulation with ACh but not FSK.   
The cellular localization of phospho-Ser157 
VASP was analyzed by PLA assays using probes 
against antibodies for phospho-Ser157 VASP and 
VASP. Close proximity (<40 nm) of the target 
epitopes on VASP results in the generation of a 
fluorescent spot indicating VASP phosphorylation. 
Phospho-Ser157 VASP was observed on the 
membrane of unstimulated and ACh or FSK 
stimulated cells; however many more spots were 
observed in cells stimulated with ACh or FSK than 
in unstimulated cells (Fig. 1F).  
Immunofluorescence was used to evaluate the 
localization of phospho-Ser157 VASP and total 
VASP in freshly dissociated cells (Fig 1G). In 
both unstimulated cells and cells stimulated with 
ACh or FSK, phospho-Ser157 VASP was only 
detected at the cell membrane, whereas VASP was 
detected in both the cytoplasm and at the cell 
membrane. The intensity of phospho-Ser157 
VASP fluorescence was much higher in ACh or 
FSK stimulated cells than in unstimulated cells. 
Treatment with BIM markedly reduced VASP 
phospho-Ser157 fluorescence in ACh stimulated 
cells and inhibited VASP localization to the 
membrane (Fig. 1G). 
Inhibition of VASP Ser157 phosphorylation 
inhibits ACh-induced smooth muscle contraction 
and actin polymerization, but it does not affect 
myosin light chain (MLC) phosphorylation 
(Fig.2).  His-EGFP VASP S157A or His-EGFP 
VASP WT was expressed in ASM tissues and 
force in response to 10-5 M ACh measured after 
expression (Fig. 2A-C). VASP S157A does not 
undergo phosphorylation at Ser157 due to the 
substitution of alanine for serine (Fig. 2C). The 
expression of VASP S157A in ASM tissues 
significantly depressed endogenous VASP Ser157 
phosphorylation and inhibited contractile force in 
response to 10 min stimulation with ACh (Fig. 2 
A-E). Neither sham treatment nor expression of 
VASP WT affected force or VASP Ser157 
phosphorylation in response to ACh.  
The proportions of F actin to G actin were 
analyzed in unstimulated and ACh-stimulated 
muscle tissues expressing VASP S157A, VASP 
WT or sham-treated tissues (Fig. 2F). Expression 
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of VASP S157A prevented the increase in the F to 
G actin ratio in response to stimulation with ACh; 
whereas expression of VASP WT or sham 
treatment had no significant effect on actin 
polymerization in response to ACh.  
ACh stimulation increased actin 
polymerization in tracheal muscle tissues, whereas 
stimulation with FSK did not (Fig. 2G). 
MLC phosphorylation was analyzed in 
unstimulated and ACh-stimulated muscle tissues 
expressing VASP S157A, VASP WT or sham-
treated tissues (Fig. 2H,I). MLC phosphorylation 
in response to ACh stimulation increased 
significantly regardless of treatment and was not 
significantly different among tissues expressing 
VASP WT, VASP S157A or sham treated tissues. 
ACh stimulates the recruitment of VASP 
and vinculin to the membrane and the formation 
of VASP–vinculin complexes; FSK stimulates the 
membrane recruitment of VASP but not vinculin 
(Fig 3). Co-immunoprecipitation analysis was 
used to assess the interaction of VASP with 
vinculin in tissues stimulated with ACh or FSK 
(Fig. 3A). Stimulation with ACh significantly 
increased the amount of vinculin that co-
precipitated with VASP compared to unstimulated 
tissues (Fig. 3B). In contrast, stimulation with FSK 
did not significantly increase the co-precipitation 
of vinculin with VASP.  
The effects of ACh and FSK on the 
interaction of VASP and vinculin were also 
evaluated using PLA in cells freshly dissociated 
from ASM tissues (Fig. 3C,D). Significantly more 
PLA spots indicating VASP-vinculin complexes 
were observed in ACh stimulated cells than in 
FSK stimulated or unstimulated cells.  
The colocalization of VASP and vinculin was 
evaluated by double immunofluorescence staining. 
Smooth muscle cells were freshly dissociated from 
tracheal smooth muscle tissues and stimulated for 
10 min with ACh or FSK or left unstimulated. In 
unstimulated cells, both VASP and vinculin were 
distributed throughout the cell cytoplasm and at 
the membrane. In cells stimulated with ACh, 
VASP and vinculin were co-localized at the cell 
membrane, and little fluorescence was observed in 
the cytoplasm for either protein. In cells stimulated 
with FSK, VASP was localized almost entirely at 
the membrane, whereas vinculin was distributed 
throughout the cytoplasm (Fig. 3E). The effect of 
FSK and ACh on the distribution of VASP and 
vinculin to the membrane versus the cytoplasm 
was analyzed in 65 cells from 3 separate 
experiments (Fig. 3F). ACh stimulation 
significantly increased the membrane localization 
of both VASP and vinculin. In contrast, FSK 
stimulated the membrane localization of VASP but 
not vinculin.  
VASP Ser157 phosphorylation is required 
for VASP recruitment to the membrane and its 
interaction with vinculin in membrane protein 
complexes (Fig.4). The role of VASP Ser157 
phosphorylation in the cellular localization of 
VASP was evaluated by analyzing the localization 
of EGFP VASP S157A and EGFP VASP WT in 
dissociated cells stimulated with either ACh or 
FSK. Stimulation with either ACh or FSK caused 
the recruitment of EGFP VASP WT to the 
membrane, but neither ACh nor FSK stimulated 
the recruitment of EGFP VASP S157A to the 
membrane (Fig 4A,B). The amount of EGFP 
VASP WT at the membrane was significantly 
higher in cells stimulated with ACh or FSK than in 
unstimulated cells (Fig. 4. B). 
PLA was used to evaluate the effect of VASP 
Ser157 phosphorylation on the interaction of 
vinculin and VASP (Fig. 4C,D).  In unstimulated 
freshly dissociated smooth muscle cells expressing 
VASP WT or VASP S157A, very few PLA spots 
were observed in the cell, indicating few protein 
complexes containing both VASP and vinculin.  In 
cells expressing VASP WT, stimulation with ACh 
caused a significant increase in the number of PLA 
spots at the cell membrane, indicating that ACh 
stimulated the formation of VASP-vinculin protein 
complexes. The expression of VASP S157A 
significantly inhibited the formation of VASP-
vinculin protein complexes in response to ACh.  
Co-immunoprecipitation analysis was also 
used to evaluate the interaction of vinculin and 
VASP in tissues expressing VASP WT or VASP 
S157A. The amount of vinculin that co-
precipitated with VASP increased significantly in 
response to ACh stimulation in sham-treated 
tissues and tissues expressing VASP WT, but not 
in tissues expressing VASP S157A (Fig. 4E,F). 
Thus, the expression of VASP S157A 
significantly inhibited the formation of VASP-
vinculin protein complexes in response to ACh in 
both tissues and isolated dissociated cells, 
demonstrating that the Ser157 phosphorylation of 
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VASP and its membrane localization are necessary 
for the interaction of VASP with vinculin. 
Vinculin Tyr1065 phosphorylation and 
activation are required for the formation of 
VASP-vinculin protein complexes at the 
membrane (Fig. 5). We previously demonstrated 
that vinculin phosphorylation at Tyr1065 is 
required for vinculin to maintain an open activated 
conformation (27). Smooth muscle tissues were 
stimulated with FSK for 10 minutes or ACh for 5 
min, then vinculin Tyr1065 phosphorylation and 
VASP phosphorylation were analyzed by 
immunoblot. Stimulation with ACh but not with 
FSK induced vinculin Tyr1065 phosphorylation, 
indicating that vinculin undergoes activation in 
response to ACh but not FSK (Fig 5A,B). In 
contrast VASP undergoes phosphorylation at Ser 
157 in response to both ACh and FSK (Fig. 5A 
and 1A-C).  
Wild type vinculin or the phosphorylation 
deficient vinculin mutant Y1065F was expressed 
in ASM tissues to determine whether vinculin 
activation is required for the formation of VASP-
vinculin complexes (Fig. 5C-G).  The interaction 
between VASP and vinculin was evaluated in 
tissue extracts by immunoprecipitation (Fig 5C,D). 
The amount of endogenous vinculin that co-
precipitated with VASP increased significantly in 
response to ACh stimulation in sham-treated 
muscles and tissues expressing WT vinculin, but 
not in tissues expressing vinculin Y1065F (Fig. 
5C,D). The expression of vinculin Y1065F did not 
affect VASP Ser157 phosphorylation in response 
to ACh. Immunofluorescence analysis confirmed 
that the expression of EGFP vinculin Y1065F also 
had no effect on the localization of VASP 
phospho-Ser157 to the membrane (Fig. 5E). 
PLA assays were used to evaluate the 
interaction of vinculin and VASP in freshly 
dissociated smooth muscle cells from tissues 
expressing vinculin Y1065F or WT vinculin (Fig. 
5F,G). Very few spots were detected in 
unstimulated cells.  In cells expressing WT 
vinculin, stimulation with ACh resulted in a 
dramatic increase in the number of PLA spots at 
the cell membrane, indicating that ACh stimulates 
formation of protein complexes containing both 
VASP and vinculin. In the cells expressing 
vinculin Y1065F, there were markedly fewer spots 
indicating VASP-vinculin complexes, 
demonstrating that vinculin activation is required 
for the interaction of VASP with vinculin in 
membrane complexes (Fig.5F,G). 
Stimulation with ACh but not FSK causes 
VASP-VASP complex formation at the 
membrane (Fig. 6).  VASP can form tetrametric 
homo-oligomers through VASP-VASP binding 
interactions at its C terminus (11,12). Although we 
could not probe specifically for VASP tetrameric 
homo-oligomers within the smooth muscle cells 
and tissues, we used PLA to assess for protein 
complexes containing multiple VASP molecules 
(VASP-VASP complexes). The effect of 
stimulation with ACh and FSK on VASP-VASP 
complex formation was investigated by using 
VASP phospho-Ser239 as a target for both + and - 
PLA probes. VASP phospho-Ser239 was chosen 
as a target epitope for the PLA probes because 
stimulation with ACh does not cause a significant 
increase in phosphorylation at this site for the first 
10 minutes (Fig 6 A,B).  Thus, an increase in the 
number of PLA spots detected after 5-10 min 
stimulation with ACh should reflect more VASP-
VASP interactions rather than an increase in 
VASP Ser239 phosphorylation.  
In cells stimulated for 10 min with ACh, 
VASP-VASP PLA spots were clearly observed on 
the membrane, but spots were barely evident in 
unstimulated cells (Fig. 6C,D). In contrast, when 
PLA for VASP-VASP interactions was performed 
on cells stimulated with FSK for 10 min, very few 
PLA spots were observed (Fig. 6C,D), even 
though FSK causes VASP Ser239 phosphorylation 
to increase by more than 5 fold within 10 min (Fig. 
6A,B).  Thus, stimulation with ACh induced the 
formation of VASP-VASP complexes by 
membrane localized VASP proteins, whereas 
stimulation with FSK did not. The fact that FSK 
induces a much higher level of VASP Ser239 
phosphorylation than ACh confirms that an 
increase in the level of VASP Ser239 
phosphorylation by itself does not result in an 
increase in the number of PLA spots.  
The effect of VASP Ser157 phosphorylation 
on VASP-VASP complex formation was 
evaluated by PLA in cells expressing VASP 
S157A and VASP WT (Fig. 6E,F). ACh-
stimulated cells expressing VASP Ser157A had 
significantly fewer VASP-VASP PLA spots than 
cells expressing VASP WT, indicating that the 
expression of VASP S157A inhibits VASP-VASP 
complex formation in response to ACh. Thus, 
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without Ser157 phosphorylation, VASP does not 
form VASP-VASP complexes, probably because it 
does not localize to the membrane.  
The effect of vinculin activation on VASP-
VASP complex formation after stimulation with 
ACh was also evaluated by PLA using cells 
expressing either WT vinculin or vinculin Y1065F. 
There were significantly more PLA spots on the 
cell membrane cells expressing WT vinculin than 
in cells expressing vinculin Y1065F (Fig. 6G,H). 
The results demonstrate that vinculin activation is 
required for the formation of VASP-VASP 
complexes at the cell membrane in response to 
stimulation with ACh. Although FSK stimulates 
VASP Ser157 phosphorylation, it does not 
stimulate vinculin activation, and thus FSK does 
not induce VASP-VASP complex formation.  
Stimulation with ACh but not FSK increases 
the interaction of VASP and profilin at the 
membrane (Fig. 7).  Profilin binds to VASP in its 
central proline-rich domain and is necessary for 
the transfer of G actin monomers to the barbed 
ends of actin filaments by VASP (9). The effect of 
ACh and FSK on complex formation between 
VASP and profilin was evaluated using co-
immunoprecipitation from tissue extracts and PLA 
in dissociated cells. Stimulation with ACh but not 
FSK significantly increased the amount of profilin 
that co-immunoprecipitated with VASP compared 
to unstimulated tissues (Fig. 7A, B). Significantly 
more PLA spots indicating VASP-profilin 
interactions were detected in ACh-stimulated cells 
than in FSK-stimulated or unstimulated cells (Fig 
7C,D). These results indicate that ACh but not 
FSK induces the binding of profilin to VASP.  
Vinculin activation is required for the 
formation of VASP-profilin complexes (Fig. 8).  
WT vinculin and the phosphorylation deficient 
mutant vinculin Y1065F were expressed in ASM 
tissues to determine whether vinculin activation is 
required for the binding of profilin to VASP.  The 
formation of complexes between VASP and 
profilin was evaluated by co-immunoprecipitation 
and PLA. The amount of profilin that co-
immunoprecipitated with VASP increased 
significantly in response to ACh stimulation in 
sham-treated muscles and tissues expressing WT 
vinculin, but not in tissues expressing vinculin 
Y1065F (Fig 8A,B).  In cells expressing WT 
vinculin, stimulation with ACh resulted in a 
significant increase in the number of PLA spots 
along the cell membrane, indicating more 
interactions between VASP and profilin. In 
contrast, in the cells expressing vinculin Y1065F, 
there were significantly fewer spots at the 
membrane indicating VASP-profilin interactions. 
The results demonstrate that vinculin activation is 
prerequisite to the interaction of profilin with 
VASP at the membrane.  
 
DISCUSSION 
Our studies demonstrate that VASP is a 
critical regulator of actin dynamics and tension 
generation during the contractile stimulation of 
ASM (Fig. 2). Our results also indicate that the 
interaction of VASP with activated vinculin at 
membrane adhesion sites is a necessary 
prerequisite for VASP-mediated molecular 
processes that are required for actin 
polymerization (Figs. 5, 6, 8).  In ASM tissues, 
contractile stimulation triggered the formation of 
VASP-VASP complexes at the membrane and also 
stimulated the interaction of profilin with VASP 
(Figs. 6-8). VASP oligomerization and its binding 
to profilin have been shown to be necessary steps 
in the VASP-mediated actin filament elongation 
process (7,9); thus, our data are consistent with a 
function for VASP as an actin elongation factor 
during contractile stimulation.  
We found that the stimulation of ASM with 
either ACh or FSK induces the phosphorylation of 
VASP on Ser157 (Fig. 1). The ACh-stimulated 
VASP Ser157 phosphorylation was mediated by 
PKC. We evaluated the role of VASP Ser157 
phosphorylation on VASP activity by expressing 
the point mutant VASP S157A in ASM tissues. 
VASP S157A expression inhibited endogenous 
VASP phosphorylation on Ser157 and prevented 
the localization of VASP to the membrane in 
response to stimulation with either ACh or FSK 
(Figs. 2,4). When VASP localization to the 
membrane was prevented, actin polymerization 
and tension generation in response to contractile 
stimulation (ACh) were inhibited, but MLC 
phosphorylation was unaffected (Fig. 2,4). We 
have previously found that in ASM, the inhibition 
of actin polymerization does not affect the 
increase in MLC phosphorylation in response to 
ACh, but that tension generation is markedly 
reduced (2,37). This suggests that MLC 
phosphorylation and actin polymerization are 
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independently regulated and that both processes 
are necessary for tension development (1). 
Although FSK induced VASP Ser157 
phosphorylation and membrane localization, FSK 
did not stimulate actin polymerization (Fig. 2), the 
formation of VASP-VASP complexes (Fig. 6), or 
the interaction of profilin with VASP (Fig. 7). 
Thus, our results suggest that VASP Ser157 
phosphorylation and the membrane localization of 
VASP are necessary but not sufficient steps to 
initiate VASP’s activity in catalyzing actin 
polymerization.  
We next evaluated the role of vinculin 
activation on the function of VASP in ASM 
tissues. We have previously shown that ACh 
stimulation induces the recruitment of vinculin to 
membrane adhesion complexes and vinculin 
activation (27,28). In the present study, we found 
that FSK does not stimulate the recruitment of 
vinculin to the membrane (Fig. 3).  Thus even 
though FSK stimulates the phosphorylation of  
VASP at Ser157 and the recruitment of VASP to 
the membrane, the phosphorylated VASP does not 
interact with vinculin.  
We expressed the vinculin point mutant 
Y1065F in ASM tissues to determine the role of 
vinculin activation on the regulation of VASP 
activity. Using FRET technology, we previously 
demonstrated that the phosphorylation of vinculin 
on Tyr1065 is necessary for vinculin to sustain its 
activated ligand-binding conformation, and that 
the mutant vinculin Y1065F localizes to the 
membrane in a closed inactive conformation and 
inhibits the activation of endogenous vinculin (Fig. 
5E) (27). In the present study, when vinculin 
activation was inhibited by the expression of 
vinculin Y1065F, contractile stimulation induced 
the phosphorylation of VASP on Ser157; but 
VASP did not interact with vinculin (Fig. 5).  Our 
observations suggest that even when both vinculin 
and VASP are localized at the membrane, VASP 
can only bind to vinculin when vinculin is in its 
open activated conformation. The inhibition of 
vinculin activation by the expression of vinculin 
Y1065F also prevented the formation of VASP-
VASP complexes and the interaction of VASP 
with profilin (Figs. 6, 8). These results suggest that 
vinculin activation and the binding of VASP to 
vinculin are necessary for VASP-mediated actin 
polymerization. The activation of vinculin may 
enable it to spatially and temporally coordinate the 
activity of VASP with other actin filament 
assembly promoting proteins.  
The phosphorylation of VASP by cyclic 
nucleotide-dependent PKA and PKG protein 
kinases is well documented in multiple cell types 
including platelets, endothelial cells and vascular 
and ASM cells (17,19-21). PKC-dependent VASP 
Ser157 phosphorylation has been reported in 
vascular smooth muscle cells activated by serum 
stimulation (19,43). Our findings are consistent 
with observations in migrating vascular 
endothelial cells that VASP phosphorylation on 
Ser157 provides a signal for VASP  localization to 
the membrane or the leading edge of the cell 
(17,19); however, these studies also reported that 
VASP Ser157 phosphorylation had a minor impact 
on actin polymerization. In contrast, we find that 
stimulus induced actin polymerization in ASM 
tissues requires the Ser157 phosphorylation of 
VASP (Fig. 2). However, our results suggest that 
this does not result from a direct effect of VASP 
phosphorylation on its actin catalytic activity; 
rather it results from the requirement that VASP 
localize to the membrane and bind to activated 
vinculin in order to initiate its actin catalytic 
function. We note that VASP Ser157 
phosphorylation does not provide a reliable 
indicator of the VASP activation with respect to 
actin dynamics. 
VASP has been shown to bind to the proline 
rich motif in the hinge region of vinculin between 
its head and tail domains; whereas the binding 
sites for vinculin on VASP are located within its 
EVH1 domain (5,29,31,44). Vinculin binding has 
also been proposed to mediate the recruitment of 
VASP to focal adhesion sites (29,31). However, 
our studies demonstrate that in ASM, VASP 
recruitment to the membrane occurs in the absence 
of vinculin recruitment, and that the recruitment of 
VASP does not depend on vinculin activation or 
the interaction of VASP and vinculin. Our results 
are thus consistent with VASP Ser157 
phosphorylation as a primary event in the 
regulation of VASP localization to adhesion 
junction complexes.  
The assembly of VASP into tetrameric homo-
oligomers is critical for the VASP-mediated 
process of actin filament elongation in vitro 
(4,8,13-15). Although VASP molecules self 
assemble into stable tetramers in vitro; there is no 
evidence regarding the oligomerization state of 
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VASP in living cells. We used a proximity ligation 
assay (PLA) to probe for multimeric VASP-VASP 
complexes in dissociated smooth muscle cells. 
Although PLA reports on complex formation 
between individual VASP proteins, it is not 
possible to confirm that the VASP protein 
complexes detected by PLA are tetramers. Other 
multimeric forms of VASP could be detected by 
PLA, as well as protein complexes that contain 
multiple VASP proteins or multimers bound in 
close proximity to an intermediary protein such as 
F-actin. In vitro studies have shown that VASP 
tetramers remain bound to the growing barbed 
ends of F-actin filaments during the elongation 
process (15). However, we observed few or no 
PLA spots in FSK stimulated cells or in 
unstimulated cells, and there were also very few 
spots in ACh-stimulated cells treated with VASP 
S157A or with vinculin Y1065F. These 
observations are consistent with the possibility that 
VASP exists in a monomeric form in unstimulated 
cells and assembles into tetramers at membrane 
sites after ACh stimulation, and that the assembly 
of VASP tetramers is prerequisite to the functional 
role of VASP in actin dynamics.  
PLA provides a very high resolution method 
for the detection of protein-protein interactions 
and protein complexes in situ (39,40). We targeted 
the phospho Ser239 epitope on VASP proteins 
using two different species antibodies; thus the 
PLA signal should reflect the interaction between 
at least two VASP monomers. The VASP Ser239 
epitope was selected as a target because VASP 
Ser239 phosphorylation does not increase above 
basal levels within the first 10 min of ACh 
stimulation (Figure 6B); therefore an increase in 
the PLA signal in response to ACh stimulation 
cannot reflect an increase in VASP Ser239 
phosphorylation. In addition, although stimulation 
of the cells with FSK causes a 5-6 fold increase in 
VASP Ser239 phosphorylation (Figure 6A,B); no 
PLA signal for VASP-VASP complexes was 
detected in FSK stimulated cells, which further 
confirms that an increase in VASP Ser239 
phosphorylation does not cause an increase in the 
PLA signal (Figure 6C). It remains possible that 
the VASP-VASP PLA signal reflects the 
formation of VASP multimeric complexes with 
other proteins in response to stimulation with ACh. 
However, if VASP is present in primarily in 
tetrametric form in unstimulated cells, FSK treated 
cells, and in cells treated with mutant VASP or 
vinculin, it is unclear why these VASP tetramers 
do not generate a PLA signal.  
Our previous studies demonstrated that the 
actin polymerization catalyst N-WASp is 
important for the activation of actin 
polymerization by contractile agonists.  We 
proposed that N-WASp mediated actin 
polymerization is likely to occur  in 
submembranous regions of the smooth muscle cell, 
and that these actin filaments are therefore most 
likely distinct from the actin filaments that 
participate in actomyosin crossbridge cycling (1). 
VASP is known to catalyze actin polymerization 
by mechanisms that are different from those of N-
WASp (4,7).  It is therefore  possible that VASP 
regulates actin polymerization in a subset of actin 
filaments that are distinct from those regulated by 
N-WASp, and that VASP-mediated actin 
polymerization constitutes a separate pathway for 
actin remodelling in ASM (2). However, as our 
data show that VASP protein interactions that are 
necessary for its actin catalytic activity occur at 
adhesome junctions at the plasma membrane and 
not in the cytoplasm; VASP mediated actin 
polymerization is most likely also confined to 
submembranous pools of actin at the cell cortex 
that are distinct from actin filaments in the 
contractile apparatus in the interior of the cell.  
Although contractile filament actin may undergo 
remodelling during ASM contraction and 
relaxation (45), mechanisms that might regulate 
the remodelling of cytoplasmic contractile actin 
have not yet been described.  
Actin polymerization is recognized as an 
essential component of the cellular response to 
agonist stimulation in many smooth muscle cell 
types; however its role in the cellular processes 
that regulate the activation of signaling pathways 
and the functional responses of the smooth muscle 
cells remain unclear. Cortical actin may serve a 
structural role to fortify linkages between the 
membrane junctional adhesome sites and actin 
filaments within the contractile apparatus. In this 
capacity, newly polymerized actin would serve to 
strengthen linkages between membrane junctional 
proteins such as alpha-actinin, vinculin and talin 
and the actin filaments that interact with myosin to 
mediate cell shortening and tension development. 
Regulation of the connections between the 
contractile apparatus and the cell membrane could 
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also serve to modify the orientation of the 
contractile filaments to adapt the cell to shape 
changes imposed by forces within its external 
environment. This could be particularly important 
in ASM which is continuously subjected to 
changes in stress and strain during breathing (46). 
However, the function of cortical actin dynamics 
may not be entirely structural: Cortical actin 
filaments may also provide a lattice for the 
assembly of junctional complexes that transduce 
signals from environmental stimuli to the interior 
of the cell. While the function and regulation of 
actin cytoskeletal structures within smooth muscle 
remain to be established, dynamic remodelling of 
the actin cytoskeletal lattice is likely to serve 
multiple functions within the ASM cell.  
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FIGURE LEGENDS 
 
FIGURE 1: VASP Ser157 phosphorylation (VASP P-Ser157) increases during stimulation with 
ACh, FSK and epinephrine in ASM tissues. A. Immunoblots of VASP and P-Ser157 VASP from 
extracts of muscle tissues either unstimulated (US) or stimulated with 10-4 M acetylcholine (ACh) for 
time periods up to 30 min. Phosphorylation of VASP on Ser157 was probed concurrently with VASP 
phospho-Ser157 and VASP antibodies. Probes were visualized using a Li-Cor Odyssey imaging system. 
Ser157 phosphorylated VASP migrated concurrently with the 50 kD VASP band (overlay). B. VASP 
Ser157 phosphorylation calculated from VASP (green) and from VASP phospho-Ser157 (red) 
immunoblots overlay very closely. In the VASP immunoblot, Ser157 phosphorylation is calculated from 
the ratio of the upper VASP 50 kD band to total VASP (both 50 kD and 46 kD bands). In the VASP 
phospho-Ser157 immunoblot, VASP Ser157 phosphorylation was calculated from the phospho-Ser157 
VASP band normalized to both VASP bands (46 and 50 kD). For each stimulus agent, VASP Ser157 
phosphorylation determined from VASP phospho-Ser157 immunoblot is normalized to maximum VASP 
Ser157 phosphorylation. C. Mean increases in VASP Ser157 phosphorylation in response to stimulation 
with ACh (n=13-20) or FSK (n=14) at each time point.  Both FSK and ACh cause significant increases in 
VASP Ser157 phosphorylation all time points after stimulation; the increase in VASP Ser157 
phosphorylation stimulated by FSK is significantly higher than that caused by ACh at all time points (p< 
0.05). D,E. Immunoblots and mean results for VASP Ser157 phosphorylation in tissues treated or not 
treated with 10μM of the PKC inhibitor Bisindolylmaleimide I (BIM) and stimulated with 10-5 M ACh or 
10-6 M FSK.  BIM causes significant inhibition of ACh stimulated but not FSK stimulated VASP Ser157 
phosphorylation. *, significantly different than corresponding No BIM tissues (n = 6).  F. In situ 
proximity ligation assays (PLA) performed in freshly dissociated ASM cells using VASP phospho-
Ser157 and VASP antibodies to determine the localization of Phospho-Ser157 VASP. Cells were 
stimulated with 10-4 M ACh, 10-6 M FSK or left unstimulated (US). Phospho-Ser157 VASP localizes at 
the ASM cell membrane in response to stimulation with either ACh or FSK. Each fluorescent spot 
indicates Ser157 phosphorylated VASP.  More spots are seen at the membrane of the ACh or FSK 
stimulated cells than of US cells. Results are representative of observations in 37 ACh stimulated cells, 26 
FSK stimulated cells and 33 US cells. G. Localization of phospho-Ser157 VASP and total VASP in 
freshly dissociated ASM cells stimulated with 10-4 M ACh, 10-6 M FSK, 10-4 M ACh and BIM or US and 
double stained for VASP and phospho-Ser157 VASP. VASP is found both at the membrane and in the 
cytoplasm of ACh stimulated, FSK stimulated and US cells, but is more concentrated at the membrane of 
the stimulated cells. Phospho-Ser157 VASP is observed only on the cell membrane in US, ACh and FSK 
stimulated cells. BIM treatment inhibits VASP recruitment to the membrane and decreases ACh-induced 
VASP Ser157 phosphorylation, but does not affect the localization of Ser157 phosphorylated VASP on 
the membrane. Representative results from 55 US cells, 47 ACh stimulated cells, 26 FSK stimulated cells 
and 15 ACh-stimulated cells treated with BIM. 
  
FIGURE 2. Expression of VASP S157A in ASM tissues inhibits ACh-stimulated contractile force 
and actin polymerization, but it does not affect myosin light chain (MLC) phosphorylation. A. 
Active stress in ASM tissues in response to stimulation with 10-5 M ACh before and after expression of 
His-EGFP VASP WT, His-EGFP VASP S157A or sham transfection. B. Expression of His-EGFP VASP 
S157A significantly depressed the force relative to Sham-treated tissues, but expression of His-EGFP 
VASP WT had no significant effect. ACh stimulated force normalized to maximal force in Sham-treated 
tissues. *, significantly different than Sham-treated tissues (n=9). C. Immunoblot against the His epitope 
of VASP immunoprecipitates from ACh-stimulated or unstimulated (US) tissues expressing His-EGFP 
VASP WT, His-EGFP VASP S157A or sham-treated. Expression of recombinant His-EGFP VASP and 
His-EGFP VASP S157A was observed in transfected tissues but not sham-treated tissues. D. Immunoblot 
against VASP and VASP phospho-Ser157 from tissues transfected with His-EGFP VASP WT, His- 
EGFP VASP S157A or sham treated. E. Expression of VASP S157A significantly inhibited endogenous 
VASP Ser157 phosphorylation in response to 10-5 M ACh stimulation (n=11 for Sham and VASP S157A, 
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n=6 for VASP WT). *, significantly different than Sham-treated tissues F. Actin polymerization was 
determined in tissues expressing VASP S157A, VASP WT or Sham-treated. Actin polymerization 
increases in response to ACh in Sham-treated and VASP WT treated muscle tissues but not in tissues 
expressing VASP S157A. *, significantly different (n=11 for Sham and VASP S157A, n=5 for VASP 
WT). G. Actin polymerization was determined in tissues stimulated with ACh, FSK or US. Actin 
polymerization significantly increased in response to ACh stimulation but not with FSK stimulation (n=4). 
H,I. MLC phosphorylation measured by urea gel electrophoresis in US or ACh stimulated tissues 
expressing VASP S157A, VASP WT or Sham-treated. There were no significant differences in MLC 
phosphorylation among ACh stimulated or US tissues subjected to different treatments (n = 5).  
 
FIGURE 3. VASP forms complexes with vinculin at the membrane of ASM cells in response to 
stimulation with ACh but not FSK.  A. Vinculin immunoprecipitates with VASP from extracts of ACh 
stimulated but not FSK stimulated or US tissues.  B. Vinculin co-immunoprecipitation with VASP was 
significantly greater in extracts from ACh stimulated than from FSK stimulated or US tissues. *, 
significantly different than US (n=9).  C. Interaction of vinculin and VASP in freshly dissociated ASM 
cells was visualized by in situ proximity ligation assays (PLA) using VASP and vinculin antibodies.  
Each fluorescent spot indicates complex between vinculin and VASP. PLA spots are observed at the 
membrane of the ACh-stimulated cells whereas very few spots are observed in FSK stimulated or US 
cells. D. Mean number of PLA spots was significantly higher in ACh stimulated smooth muscle cells than 
in FSK stimulated or US cells. *, significantly higher than US (n=27-35 cells). E. Immunofluorescence 
images of dissociated cells stimulated with ACh, FSK or left unstimulated (US) and then double stained 
for VASP (green) and vinculin (red).  ACh increases the localization of both VASP and vinculin at the 
cell membrane.  FSK increases the localization of VASP at the cell membrane, but has little effect on 
vinculin localization. Merged images show colocalization of VASP and vinculin in yellow. F. Mean 
ratios of membrane to cytoplasmic pixel intensity for VASP and vinculin. The ratio of membrane to 
cytoplasmic VASP localization is significantly higher in ACh (n=28) and FSK (n=15) stimulated cells 
than in US cells (n=22). The membrane/cytoplasm ratio of vinculin localization is significantly higher in 
ACh stimulated cells than in US cells, but it is not significantly increased in FSK stimulated cells.  
 
FIGURE 4. Expression of EGFP VASP S157A inhibits the interaction of VASP and vinculin in 
response to ACh stimulation in ASM tissues. A. Localization of recombinant EGFP-VASP WT and 
EGFP VASP S157A in freshly dissociated ASM cells. Recombinant VASP was visualized in fixed cells 
by EGFP fluorescence.  EGFP VASP WT localizes to the cell membrane in response to ACh or FSK 
stimulation, but EGFP VASP S157A is distributed throughout the cytoplasm and does not localize to the 
cell membrane after ACh or FSK stimulation. B. Mean results for EGFP VASP WT and EGFP VASP 
S157A cellular localization in US, ACh or FSK stimulated smooth muscle cells. Values represent the 
ratio of membrane to cytoplasmic pixel intensity for each cell. * indicates significant difference from US 
cells (n=22-28).  C. In situ proximity ligation assays (PLA) were performed to visualize the interaction of 
vinculin with VASP in freshly dissociated ASM cells from tissues expressing VASP WT or VASP S157A.  
Each fluorescent spot indicates a complex between vinculin and VASP.  D. Mean results for effects of 
VASP WT (n=46 cells) and VASP S157A (n=30 cells) on the interaction of VASP and vinculin in US 
and ACh stimulated cells. The expression of VASP S157A significantly reduces the interaction of VASP 
with vinculin in ACh stimulated cells.  *, significantly different.  E. Co-immunoprecipitation of vinculin 
after ACh stimulation was detected in VASP immunoprecipitates from tissues expressing VASP WT or 
Sham-treated, but not in tissues expressing VASP S157A. F. Co-precipitation of vinculin with VASP 
increases significantly in Sham-treated tissues and tissues expressing VASP WT but not in tissues 
expressing VASP S157A (n=4). 
 
FIGURE 5. Vinculin activation is required for the ACh induced interaction of VASP with vinculin.   
A. Immunoblots of vinculin P-Tyr1065 vinculin and VASP from 6 ASM tissues stimulated with 10-4M 
ACh, 10-6 M FSK or unstimulated (US). ACh stimulation increases vinculin phosphorylation at Tyr1065, 
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but FSK has no effect on the vinculin Tyr1065 phosphorylation. VASP phosphorylation at Ser157 
increases with both ACh and FSK stimulation. B. Vinculin Tyr1065 phosphorylation increases 
significantly with ACh stimulation but not with FSK stimulation. *, significantly different than US (n=5).  
C. Co-precipitation of vinculin was observed in VASP immunoprecipitates after ACh stimulation of 
tissues expressing vinculin WT or Sham-treated, but not in tissues expressing vinculin Y1065F. D. Co-
precipitation of vinculin with VASP increases significantly in Sham-treated tissues and tissues expressing 
vinculin WT but not in tissues expressing vinculin Y1065F. VASP Ser157 phosphorylation increased 
significantly in response to ACh in all 3 treatment groups. *, significantly different than US (n=4). E. 
Localization of endogenous Ser157 phosphorylated VASP in freshly dissociated ASM cells expressing 
EGFP vinculin Y1065F or EGFP WT vinculin. Cells were double stained for VASP phospho-Ser157 and 
for GFP to visualize recombinant vinculin. In cells expressing either vinculin WT or vinculin Y1065F, 
endogenous Ser157 phosphorylated VASP was localized on the membrane. Both EGFP-vinculin and 
vinculin Y1065F localize to the cell membrane in response to ACh. F. In situ proximity ligation assays 
(PLA) using VASP and vinculin antibodies were performed to visualize complexes between vinculin and 
VASP in freshly dissociated ASM cells from tissues expressing vinculin WT or vinculin Y1065F.  Each 
fluorescent spot indicates interaction between vinculin and VASP.  The interaction of VASP with 
vinculin in ACh stimulated cells is inhibited in cells expressing vinculin Y1065F but not in cells 
expressing vinculin WT. G. Mean number of PLA spots indicating vinculin-VASP complexes for each 
treatment. Significantly more spots were observed in ACh-stimulated cells expressing vinculin WT (n=23) 
than in cells expressing vinculin Y1065F (n=27). *, significant difference. 
 
 FIGURE 6. Stimulation of ASM cells with ACh but not FSK induces VASP-VASP complex 
formation. VASP-VASP complex formation is inhibited by the expression of VASP S157A or 
vinculin Y1065F.  A. Immunoblots of VASP Ser239 phosphorylation in tissue extracts in response to 
stimulation with ACh or FSK. Ser239 phosphorylated VASP was detected in both bands of VASP using a 
site-specific Ser239 antibody. B. VASP Ser239 phosphorylation increased significantly more in response 
to FSK (n=7) than in response to ACh (n=6). (Values are fold increase over US).*, significantly greater 
than US. C. In situ proximity ligation assays (PLA) using VASP phospho-Ser239 mouse and rabbit 
antibodies to visualize VASP-VASP complex formation in freshly dissociated ASM cells.  Each 
fluorescent spot indicates a VASP-VASP interaction. VASP complex formation increases in smooth 
muscle cells in response to ACh stimulation but not in response to FSK stimulation.  D. Mean results for 
VASP-VASP complex formation in response to FSK or ACh.  *, significantly more PLA spots were 
observed at the membrane of the ACh-stimulated cells (n=21) than in FSK stimulated (n=29) or US cells 
(n=22). E. PLA was performed to visualize VASP-VASP complex formation in cells expressing VASP 
WT or VASP S157A.  The expression of VASP S157A but not VASP WT inhibits VASP-VASP complex 
formation in ACh stimulated cells.  F. *, mean number of PLA spots was significantly higher in ACh 
stimulated ASM cells expressing VASP WT (n=22) than in cells expressing VASP S157A (n=25). G. 
PLA was performed to visualize VASP-VASP complex formation in cells expressing vinculin WT or 
vinculin Y1065F. The expression of vinculin Y1065F but not vinculin WT inhibits VASP-VASP 
complex formation in ACh stimulated cells. H. The total number of PLA spots was significantly higher in 
ACh stimulated ASM cells expressing Vinculin WT than in cells expressing Vinculin Y1065F. *, mean 
number of PLA spots was significantly higher in ACh stimulated ASM cells expressing vinculin WT 
(n=24) than in cells expressing vinculin Y1065F (n=27). 
 
FIGURE 7.  ACh stimulation increases the interaction of profilin with VASP in ASM cells. A. 
Immunoblots from tissues stimulated with ACh, FSK or unstimulated (US). Co-precipitation of profilin 
with VASP increases in response to stimulation with ACh but not with FSK.  B. *, significantly more 
profilin co-precipitated with VASP from ACh-stimulated tissues than from US or FSK stimulated tissues 
(n=3).  C. In situ proximity ligation assays (PLA) in freshly dissociated ASM cells to visualize the 
formation of complexes between profilin and VASP. Each fluorescent spot indicates a complex between 
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profilin and VASP. D. *, significantly more PLA spots were observed in ACh stimulated ASM cells 
(n=15) than in FSK stimulated (n=18) or US cells (n=18).  
 
FIGURE 8. Expression of vinculin Y1065F inhibits the VASP-profilin interaction.  A. Immunoblots 
from VASP immunoprecipitates from tissues expressing vinculin WT, vinculin Y1065F or sham-treated 
with or without ACh stimulation.  B. The amount of profilin that co-precipitated with VASP during ACh 
stimulation increases significantly in sham treated tissues and tissues expressing vinculin WT but not in 
tissues expressing vinculin Y1065F (n=5). *, significantly different from US. C. PLA in cells expressing 
vinculin WT or vinculin Y1065F to visualize the formation of complexes between profilin and VASP. 
Each fluorescent spot indicates a complex between profilin and VASP.  D. *, the total number of PLA 
spots was significantly higher in ACh-stimulated cells expressing vinculin WT (n=21) than in cells 
expressing vinculin Y1065F (n=21). 
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